This is because of their roles in several key cellular functions and because disruption to the VAPB-PTPIP51 interaction is seen in Alzheimer’s disease, Parkinson’s disease, and FTD/ALS (De Vos et al., 2012; Stoica et al., 2014; Galmes et al., 2016; Stoica et al., 2016; Gomez-Suaga et al., 2017; Paillusson et al., 2017; Gomez-Suaga et al., 2019; Lau et al., 2020; Yeo et al., 2021; Gomez-Suaga et al., 2022). This evidence concerns the gene RMDN3 and Parkinson disease.